Ocugen Announces Studies Showing COVAXIN Potentially Effective against Three Key Variants of SARS-CoV-2

Ocugen, Inc. announced that in a new study, scientists at Indian Council of Medical Research-National Institute of Virology have found that COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2.